SCHEMBL1344245

SCHEMBL1344245

CC(C)(C)OC(=O)N1CCN(CCCN2CCC[C@@H]2CO)C(=O)C1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 2/20 0.37
MEN1 O00255 1/20 0.37
ALDH1A1 P00352 1/20 0.37
MAPT P10636 1/20 0.37
KMT2A Q03164 1/20 0.37
TP53 P04637 1/20 0.36
SPHK2 Q9NRA0 2/20 0.35
SPHK1 Q9NYA1 2/20 0.35
DDB1 Q16531 1/20 0.35
CRBN Q96SW2 1/20 0.35
OPRD1 P41143 2/20 0.35
NR1H2 P55055 1/20 0.35
PDE4B Q07343 1/20 0.35
PDE7A Q13946 1/20 0.35
HPGD P15428 1/20 0.34
CHRM2 P08172 1/20 0.34
CHRM1 P11229 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1341937 1.00 HRH3 (0.37) HRH3MEN1ALDH1A1MAPTKMT2A
SCHEMBL1341939 1.00 HRH3 (0.37) HRH3MEN1ALDH1A1MAPTKMT2A
SCHEMBL1341603 0.80 HRH3 (0.39) HRH3ALDH1A1SPHK2SPHK1OPRD1
SCHEMBL1341604 0.80 HRH3 (0.39) HRH3ALDH1A1SPHK2SPHK1OPRD1
SCHEMBL1343264 0.79 HRH3 (0.42) HRH3MEN1KMT2ANR1H2HPGD
SCHEMBL1343620 0.79 MEN1 (0.39) HRH3MEN1ALDH1A1MAPTKMT2A
SCHEMBL1342732 0.79 NR1H2 (0.45) MEN1ALDH1A1MAPTKMT2ATP53
SCHEMBL1344188 0.78 CHRM2 (0.39) MEN1ALDH1A1MAPTKMT2ATP53
SCHEMBL1583540 0.78 CNR2 (0.40) ALDH1A1MAPTDDB1CRBNNR1H2
SCHEMBL4005175 0.78 NR1H2 (0.41) MEN1ALDH1A1MAPTKMT2ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063042-B2 Heterocyclic compounds HOFFMANN-LA ROCHE INC. (US) 2011-11-22 US disclosed
EP-2220055-A2 NOVEL HETEROCYCLYL COMPOUNDS AND THEIR USE AS CHEMOKINE ANTAGONISTS F. Hoffmann-La Roche AG (CH) 2010-08-25 EP disclosed
US-20090023713-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE, INC. 2009-01-22 US disclosed
WO-2009010429-A2 NOVEL HETEROCYCLYL COMPOUNDS AND THEIR USE AS CHEMOKINE ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023713-A1 HETEROCYCLIC COMPOUNDS CCR5, CCR3, CCR2 HRH3 137/4885MEN1 3201/4885ALDH1A1 2364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.